Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Arthritis & Rheumatology

Topics

Medicine

Cancer Oncology

Pathology

Internal Medicine

Hematology

Show all topics

DOI

10.1002/art.39808

License

CC-BY-NC-ND

Other Formats

PDF